- Home
- VYGR vs QURE Comparison
VYGR vs QURE Comparison
Compare VYGR & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- QURE
- Stock Information
- Founded
- VYGR 2013
- QURE 1998
- Country
- VYGR United States
- QURE Netherlands
- Employees
- VYGR N/A
- QURE N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- VYGR Health Care
- QURE Health Care
- Exchange
- VYGR Nasdaq
- QURE Nasdaq
- Market Cap
- VYGR 386.1M
- QURE 432.6M
- IPO Year
- VYGR 2015
- QURE 2007
- Fundamental
- Price
- VYGR $5.66
- QURE $5.78
- Analyst Decision
- VYGR Strong Buy
- QURE Buy
- Analyst Count
- VYGR 8
- QURE 6
- Target Price
- VYGR $17.00
- QURE $17.00
- AVG Volume (30 Days)
- VYGR 590.4K
- QURE 798.3K
- Earning Date
- VYGR 11-12-2024
- QURE 11-05-2024
- Dividend Yield
- VYGR N/A
- QURE N/A
- EPS Growth
- VYGR N/A
- QURE N/A
- EPS
- VYGR 0.47
- QURE N/A
- Revenue
- VYGR $163,784,000.00
- QURE $28,587,000.00
- Revenue This Year
- VYGR N/A
- QURE $157.96
- Revenue Next Year
- VYGR N/A
- QURE N/A
- P/E Ratio
- VYGR $12.13
- QURE N/A
- Revenue Growth
- VYGR 3.40
- QURE N/A
- 52 Week Low
- VYGR $5.19
- QURE $3.73
- 52 Week High
- VYGR $11.72
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- VYGR 38.70
- QURE 43.09
- Support Level
- VYGR $5.19
- QURE $5.50
- Resistance Level
- VYGR $5.59
- QURE $7.96
- Average True Range (ATR)
- VYGR 0.39
- QURE 0.58
- MACD
- VYGR -0.15
- QURE -0.16
- Stochastic Oscillator
- VYGR 20.76
- QURE 16.48
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.